Universe
Scientific Publishing

Research progress on dexmedetomidine-assisted clinical treatment of intracranial aneurysms

Junming Shi

Guangzhou Medical University, Guangzhou 510000, China

Abstract: This study comprehensively analyzes the application and clinical progress of dexmedetomidine in the treatment of intracranial aneurysms. Intracranial aneurysms have become an important challenge in the field of neurosurgery due to their risk of rupture and high mortality rate. In this context, the use of dexmedetomidine is particularly important, especially in perioperative management to maintain hemodynamic stability and provide effective sedation. A review of research shows that dexmedetomidine, due to its α2-adrenoceptor agonist properties, can effectively reduce intraoperative blood pressure and heart rate fluctuations, reduce changes in intracranial pressure, and reduce the risk of aneurysm rupture. Furthermore, it shows potential advantages in reducing postoperative complications and accelerating recovery. However, its suitability in specific patient groups and safety of long-term use still require further study. In the Discussion section, we highlight the advantages of dexmedetomidine, such as stable sedation and subtle effects on the cardiovascular system, while pointing out the limitations and challenges of its use in specific patient populations. Future research should focus on determining the optimal clinical use of dexmedetomidine, including dosage, timing of administration, and suitability for specific patient populations. Taken together, dexmedetomidine has shown obvious advantages in perioperative management of intracranial aneurysm surgery, but its optimal application method and long-term safety still require more clinical research support. This study provides important reference information for future clinical practice and provides a scientific basis for further optimizing treatment strategies for patients with intracranial aneurysms.

Keywords: Dexmedetomidine; Intracranial Aneurysm; Clinical Treatment

1. Introduction

Intracranial aneurysm is a serious neurosurgical disease that refers to the local expansion or tumor-like protrusion of the cerebral blood vessel wall. The danger of this disease is a ruptured aneurysm, which can lead to subarachnoid hemorrhage, an acute, high-mortality cerebrovascular accident. The clinical manifestations of intracranial aneurysms are diverse and may include symptoms such as headache, vision problems, and facial numbness. Because these symptoms are often subtle, the diagnosis and treatment of aneurysms presents significant challenges. Dexmedetomidine is an α2-adrenoceptor agonist with sedative, anxiolytic, analgesic, and heart rate control effects. It is widely used for sedation in the ICU (intensive care unit) setting, especially in patients requiring prolonged sedation and mechanical ventilation. The advantage is the ability to provide stable sedation without compromising patient cooperation while reducing the need for other sedatives and opioids. In neurosurgery, especially intracranial surgery, maintaining patient stability is crucial. A key challenge in intraoperative and postoperative management is ensuring patient hemodynamic stability and appropriate sedation levels. Dexmedetomidine has shown potential in this regard, particularly in controlling heart rate, reducing stress responses, and maintaining hemodynamic stability. This is particularly important for patients undergoing intracranial aneurysm surgery, as intraoperative blood pressure fluctuations may increase the risk of aneurysm rupture or affect postoperative recovery. For the treatment of intracranial aneurysms, surgery remains the main treatment method, including microsurgery and interventional therapy. During these surgeries, effective patient sedation and analgesia management while maintaining reliable neurologic monitoring are critical to the success of the procedure. In this context, the study of the application of dexmedetomidine in intracranial aneurysm surgery aims to improve surgical safety, reduce the risk of complications, and optimize patients' postoperative recovery. Given the unique pharmacological effects of dexmedetomidine and its successful use in other surgical procedures, it is particularly important to explore its role in the treatment of intracranial aneurysms.

2. Clinical treatment of intracranial aneurysms

Intracranial aneurysms, localized bulges in cerebral vessel walls, pose significant risks due to potential rupture, leading to subarachnoid

hemorrhage (SAH) with high mortality and disability rates. Early detection and intervention are crucial, as aneurysms often remain asymptomatic until rupture, presenting with severe headaches, nausea, loss of consciousness, or even death. Unruptured aneurysms may cause headaches, visual disturbances, or neurological deficits by compressing nearby structures.

Treatment primarily involves microsurgical clipping or endovascular embolization. Clipping places a metal clip on the aneurysm neck to block blood flow, preventing rupture. Endovascular coiling involves inserting materials to embolize the aneurysm, reducing rupture risk. Post-rupture, drug therapy manages SAH by controlling cerebral edema, intracranial pressure, and complications. Beta-blockers help regulate blood pressure, minimizing rebleeding risks.

Perioperative management focuses on hemodynamic stability and sedation to mitigate blood pressure and heart rate fluctuations from surgical stress, which may elevate rupture risks. Dexmedetomidine, an α2-adrenoceptor agonist, provides stable sedation and analgesia, reducing reliance on other sedatives while aiding hemodynamic control. Its properties highlight its potential role in perioperative care for intracranial aneurysm surgeries.

3. The role of dexmedetomidine in the treatment of intracranial aneurysms

In neurosurgery, especially intracranial surgery, maintaining patient hemodynamic stability and appropriate sedation levels is crucial. The use of dexmedetomidine in this field is mainly based on its sedative and stabilizing effects on the cardiovascular system. A study conducted by Smith et al showed that dexmedetomidine showed good effects in maintaining intracranial pressure (ICP) and cerebral perfusion pressure (CPP), which is particularly important for the maintenance of cerebral hemodynamics. In a study conducted by Wang et al., researchers found that dexmedetomidine performed better than traditional drugs in postoperative sedation and analgesia, helping to improve patient comfort and postoperative recovery. Intracranial aneurysm surgery requires delicate operations, and hemodynamic stability during surgery is crucial. Dexmedetomidine shows potential use in this type of surgery due to its ability to reduce blood pressure and heart rate fluctuations. The study by Johnson et al. showed that the use of dexmedetomidine during intracranial aneurysm surgery can significantly reduce intraoperative blood pressure and heart rate fluctuations, helping to reduce the risk of aneurysm rupture. Research by Zhang Hua and others found that patients who used dexmedetomidine recovered faster after surgery and had a shorter stay in the ICU, showing good postoperative recovery effects. Management of intracranial pressure is crucial during intracranial aneurysm surgery. Dexmedetomidine may be beneficial in the management of ICP due to its effects on the central nervous system. A study conducted by Lee et al found that dexmedetomidine can effectively control intracranial pressure and is particularly important for preventing postoperative intracranial hypertension symptoms. Complications after intracranial aneurysm surgery may include cerebral edema and rebleeding. Dexmedetomidine may reduce the risk of these complications by stabilizing hemodynamics and improving neurological recovery. Studies by Gupta et al. have shown that the application of dexmedetomidine is associated with a reduction in complications after intracranial aneurysm surgery, especially in reducing postoperative cerebral edema and improving neurological recovery. Although dexmedetomidine has shown many advantages in the short term, its safety and efficacy in the long term require further study. A study conducted by Chen Ming et al. pointed out that although the short-term application of dexmedetomidine is safe and effective, data on its long-term application are still relatively limited and more clinical trials are needed to verify it. In summary, the use of dexmedetomidine in intracranial aneurysm surgery shows multiple potential advantages, including maintaining hemodynamic stability, reducing postoperative complications, and improving the overall recovery of patients. However, more in-depth research and clinical trials are needed to further clarify the safety and efficacy of its long-term application.

4. Clinical research and case analysis

Dexmedetomidine has gained attention in intracranial aneurysm surgery due to its hemodynamic stabilizing effects. Clinical trials show it effectively manages heart rate and blood pressure, reducing intraoperative bleeding risk and postoperative complications. Its sedative and analgesic properties provide pain relief while allowing early neurological assessment, contributing to faster recovery and shorter hospital stays.

Additionally, dexmedetomidine may help mitigate cerebral edema and vasospasm post-surgery by stabilizing hemodynamics and reducing surgical stress. Case studies highlight its benefits: a 60-year-old female with an unruptured aneurysm remained hemodynamically sta-

ble throughout surgery with no postoperative complications, while a 55-year-old male experienced effective pain control, early neurological assessment, and quicker recovery.

Beyond sedation, dexmedetomidine's ability to prevent hemodynamic fluctuations is crucial in reducing intraoperative bleeding risks. Its role in minimizing postoperative complications suggests potential cost-saving benefits and improved patient outcomes. However, further research is necessary to determine optimal dosing, safety, and long-term efficacy across diverse patient populations.

5. Discussion

The utilization of dexmedetomidine in intracranial aneurysm surgery is underpinned by its dual role as a sedative and a stabilizer of hemodynamics. Clinical evidence demonstrates its effectiveness in modulating intraoperative blood pressure and heart rate, alongside minimizing fluctuations in intracranial pressure, thus diminishing the likelihood of aneurysm rupture. However, its role in enhancing postoperative recovery and curtailing complications remains to be substantiated by further empirical studies. One of dexmedetomidine's pivotal benefits in this surgical context is its capacity to deliver consistent sedation with minimal cardiovascular disturbance, crucially mitigating the blood pressure and heart rate variations induced by intraoperative stress and pain. This aspect necessitates further exploration, particularly concerning its safety and adaptability for specific patient demographics, including those with significant cardiac, hepatic, or renal impairments, and the evaluation of its long-term application. In comparison with other sedatives like propofol and benzodiazepines, dexmedetomidine might offer superior efficacy in attenuating cardiovascular responses and ensuring hemodynamic equilibrium during perioperative management, a hypothesis that awaits confirmation through rigorous randomized controlled trials and systematic analyses. Despite its prospective merits in intracranial aneurysm surgery, the clinical integration of dexmedetomidine is not without challenges. These include determining the optimal dosage and administration timing, and balancing sedation with the risk of excessive suppression or hemodynamic instability. Future research endeavors should concentrate on establishing the most effective clinical application of dexmedetomidine, encompassing aspects such as dosing, timing, and patient-specific suitability. Additional randomized controlled trials and meta-analyses are imperative to authenticate dexmedetomidine's efficacy and safety in this surgical domain, thereby fortifying the evidence base for its clinical use. At this juncture, dexmedetomidine emerges as a potentially valuable agent in intracranial aneurysm surgeries, particularly in maintaining hemodynamic stability and facilitating effective sedation. Nonetheless, an expanded corpus of clinical research is essential to elucidate its enduring impacts and safety profile, especially in specialized patient groups. For healthcare practitioners, judicious application of dexmedetomidine, while vigilantly considering the overall patient condition and potential risks, is critical in enhancing surgical safety and promoting postoperative convalescence.

The exploration of dexmedetomidine's utility in intracranial aneurysm surgery extends beyond its primary roles as a sedative and hemodynamic stabilizer. Its efficacy in managing intraoperative cardiovascular dynamics presents a promising prospect for reducing surgical risks associated with aneurysm rupture. However, the spectrum of its effectiveness, particularly in enhancing postoperative outcomes and diminishing complications, remains an area ripe for in-depth research. This necessity becomes more pronounced when considering patient subsets with complex comorbidities, such as severe cardiovascular, hepatic, or renal disorders, where the safety and appropriateness of dexmedetomidine require rigorous evaluation.In contrast to traditional sedatives like propofol and benzodiazepines, dexmedetomidine's potential to modulate cardiovascular responses with greater precision could mark a significant advance in perioperative care. This proposition, however, demands validation through comprehensive randomized controlled trials and systematic reviews to establish its efficacy and safety unequivocally.The challenges in integrating dexmedetomidine into clinical practice for intracranial aneurysm surgeries are multifaceted. Key among these is the determination of the most effective dosage and timing of administration to optimize patient outcomes while avoiding potential risks like oversedation or hemodynamic instability. Future research should, therefore, be geared towards delineating the precise clinical parameters for dexmedetomidine use, ensuring it caters effectively to diverse patient needs.Moreover, the deployment of additional randomized controlled trials and meta-analyses is crucial. These studies should aim to solidify the evidence base regarding dexmedetomidine's role in intracranial aneurysm surgeries, particularly focusing on its long-term effects and safety across varied patient populations.In the current landscape of clinical practice, dexmedetomidine shows considerable promise, especially in maintaining hemodynamic balance and providing effective sedation during intracranial aneurysm surgeries. However, the imperative for more expansive clinical studies to further elucidate its

long-term impacts and safety, particularly for special patient groups, cannot be overstated. For clinicians, the judicious use of dexmedetomidine, aligned with a keen awareness of each patient's overall health status and potential risks, is crucial. This approach is paramount not only in enhancing surgical safety but also in improving the quality of postoperative recovery, thereby contributing significantly to the overall success of intracranial aneurysm management strategies.

6. Conclusion

The study highlights dexmedetomidine's efficacy in managing perioperative complications in intracranial aneurysm surgeries. Its α2-adrenoceptor agonist properties contribute to maintaining hemodynamic stability, reducing intraoperative blood pressure and heart rate fluctuations, and minimizing changes in intracranial pressure. This reduces the risk of aneurysm rupture and promotes faster recovery post-surgery.Dexmedetomidine offers stable sedation with minimal impact on the cardiovascular system, which is crucial in the delicate context of neurosurgery.The study acknowledges certain limitations in the use of dexmedetomidine. It points out the need for more research to understand its suitability across different patient groups and the safety of its long-term use.The study suggests that future research should focus on determining the optimal dosage, timing, and patient suitability for dexmedetomidine use. This would help in refining its application method and ensuring long-term safety.hile dexmedetomidine has shown clear benefits in the perioperative management of intracranial aneurysms, its optimal application and long-term safety need more clinical research. The study aims to provide reference information for clinical practice and contribute to optimizing treatment strategies for intracranial aneurysm patients.

References

[1]Wei S ,Wei L ,Mengyuan Z , et al. Dexmedetomidine Protects Cortical Neurons from Propofol-Induced Apoptosis via Activation of Akt-IKK-NF-κB Signaling Pathway by α_{2A}-adrenoceptor. [J]. Applied biochemistry and biotechnology, 2023,

[2]M V S ,Oleg S ,Sandeep K , et al. Transcriptomics of intracranial aneurysms: current state and opportunities in flow diversion. [J]. Journal of neurosurgery, 2023, 1-9.

[3]Guangbao H ,Hongwei N ,Kai W , et al. Dexmedetomidine attenuates the neuroinflammation and cognitive dysfunction in aged mice by targeting the SNHG14/miR-340/NF-κB axis. [J]. Biomedical reports, 2023, 19 (6): 100-100.

[4]Yang S L ,Margot K ,Nancy T , et al. Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study. [J]. Critical care medicine, 2023.

[5]Wenting W ,Yu J ,Peiyao Z , et al. Impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: a retrospective propensity score matching analysis. [J]. BMJ open, 2023, 13 (11): e073675-e073675.

[6]Anthony G K ,Alexander L ,Michaela N , et al. Periarticular infiltration used in total joint replacements: an update and review article [J]. Journal of Orthopaedic Surgery and Research, 2023, 18 (1): 859-859.

[7]Huayue L ,Juan Z ,Ke P , et al. Protocol: dexmedetomidine on myocardial injury after noncardiac surgery—a multicenter, double-blind, controlled trial [J]. Perioperative Medicine, 2023, 12 (1): 57-57.

[8]L A H ,W G J ,W J O , et al. Natural history and growth rate of intracranial aneurysms in Loeys-Dietz syndrome: implications for treatment. [J]. Journal of neurosurgery, 2023, 1-8.

[9]Hanafy E S ,Mahmoud M E ,Mohamed R G , et al. Ultrasound-guided continuous erector spinae plane block vs continuous thoracic epidural analgesia for the management of acute and chronic postthoracotomy pain: a randomized, controlled,double-blind trial [J]. PAIN Reports, 2023, 8 (6): e1106-.

[10]A. D B ,A. D S ,Kristian S V . Understanding intracranial aneurysm sounds via high-fidelity fluid-structure-interaction modelling [J]. Communications Medicine, 2023, 3 (1): 163-163.

[11]Erfaneh A ,Hesameddin M ,Shirin P , et al. Comparison of adding magnesium sulfate, dexmedetomidine and ondansetron to lidocaine for gargling before laryngoscopy and endotracheal intubation to prevent sore throat: a randomized clinical trial. [J]. Medical gas research, 2024, 14 (2): 54-60.

[12]Robert V ,Roland K ,Erin T , et al. Peripheral nerve block adjuncts: which medication to choose? A narrative review of the current literature. [J]. Pain management, 2023.

[13]Toru Y ,Satoru T ,Terushige T , et al. Effectiveness of Keyhole Clipping of Unruptured Intracranial Aneurysms Detected by “Brain Dock” in Healthy Japanese Adults. [J]. Neurologia medico-chirurgica, 2023.

[14]Xu Y ,Shuhua Z ,Qicheng H , et al. Quantitative Evaluation of Hemodynamic Changes After Multiple Intracranial Aneurysms Occlusion using CFD. [J]. World neurosurgery, 2023.

[15]Trey S ,Korde S ,M A E . Dexmedetomidine - An Alternative to Midazolam in the Treatment of Ketamine-Induced Emergence Delirium: A Systematic Review. [J]. Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2023.

[16]R J C ,L A G ,Justin V , et al. Pediatric anterior choroidal artery aneurysm successfully coiled after re-rupture. [J]. The neuroradiology journal, 2023, 19714009231212365-19714009231212365.

[17]Ahmed A M M A A ,Elizabeth K M ,Olivia H , et al. The effects of dexmedetomidine on intraoperative neurophysiologic monitoring modalities during corrective scoliosis surgery in pediatric patients: A systematic review. [J]. Paediatric anaesthesia, 2023.

[18]Nazeem G B S ,Gabriale B B S ,EL R E A S E A A , et al. Dexmedetomidine or magnesium to control agitations in patients undergoing tonsillectomy: randomised controlled study [J]. Ain-Shams Journal of Anesthesiology, 2023, 15 (1):

[19]Lu M ,Youyang H . Application of Dexmedetomidine Intravenously Infusion Before Induction of Anesthesia in Segmentectomy of Lung Cancer Patients. [J]. Alternative therapies in health and medicine, 2023.

[20]Yongjian L ,Guangfen Y ,Congcan J , et al. The Application Value of Esketamine and Dexmedetomidine in Preventing Postoperative Delirium and Hyperalgesia in Elderly Patients with Thoracic Anesthesia. [J]. Alternative therapies in health and medicine, 2023.

[21]Yujing W ,Jing J ,Jie C , et al. Impacts of morphology parameters on the risk of rupture in intracranial aneurysms: statistical and computational analyses [J]. Scientific Reports, 2023, 13 (1): 18974-18974.

[22]Yaqin Z ,Ziying J ,Shanshan W . Bone Marrow Mesenchymal Stem Cells Release miR-378a-5p-Carried Extracellular Vesicles to Alleviate Rheumatoid Arthritis. [J]. Journal of innate immunity, 2023.

[23]A. W P F ,Tariq J ,Rafael L S M , et al. A systematic review and meta-analysis of Surpass flow diverter for the treatment of intracranial aneurysms [J]. Egyptian Journal of Neurosurgery, 2023, 38 (1):

[24]Youngwon K ,Chul Y Y ,Young N K , et al. The effects of perioperative dexmedetomidine infusion on hemodynamic stability during laparoscopic adrenalectomy for pheochromocytoma: a randomized study
 [J]. Frontiers in Medicine, 2023, 10

[25]Loreta G . ICU Analgesia and Sedation: Is It Time to Change Our Practice?* [J]. Critical Care Medicine, 2023, 51 (11): 1600-1602.

[26]Francesco M ,Carmine P ,Saverio P , et al. Dexamethasone and dexmedetomidine together as adjuvants of ropivacaine 0.15% for a brachial plexus block lasting 20 hours. [J]. Minerva anestesiologica, 2023, 89 (11): 1052-1054.

[27]Christina L ,AnneMarie O ,Sandra L , et al. Intrathecal dexmedetomidine analgesia after Cesarean delivery: a feasibility trial. [J]. Canadian journal of anaesthesia = Journal canadien d’anesthesie, 2023.

[28]Laurent S ,Vincent C ,Jildaz C , et al. CLinical EValuation of WEB 17 device in intracranial aneuRysms (CLEVER): procedural, 30-day and 1-year safety results for ruptured and unruptured aneurysms. [J]. Journal of neurointerventional surgery, 2023.

Author Bio:

Junming Shi (2002.12-) is a Han Chinese male from Shenzhen, Guangdong Province, China, with a Bachelor’s degree.Research interests: clinical anaesthesiology